Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs

Bullboard Posts

Post by TheDon4on Aug 02, 2005 11:05am

184 Views

Post# 9347730

Game on....

SJ looks to have a potential winner with this Halo in IMHO borrowed this paragraph from StocksJournal's report this morning. To see the full report, go to www.stocksjournal.com and click the link ( for the full report )and fill out the short form...worth the read, best to all. The buzz on the “street” is that Halo Resources Ltd. (TSX.V:HLO; OTC.BB:HLOSF; FSE:HRL) could fast become a developer by rapidly bringing one of its gold properties into production. The signs of success underpinning Halo have been present for months, as the Company continues to develop a business strategy that boasts a compelling investment blueprint. A potential pay day for shareholders may soon be crystallized, as Halo continues to increase reserve estimates through rigorous drill programs and shows signs of moving from exploration status to producer.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports